A Study of GC101 TIL in Advanced Melanoma (10hospital)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT ID

NCT05098184

Phase

EARLY_PHASE1

Sponsor

Shanghai Juncell Therapeutics

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Tumor Infiltrating Lymphocyte

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Age: 18 years to 75 years;
Histologically diagnosed as primary/relapsed/metastasized melanoma;
Expected life-span more than 3 months;
Karnofsky≥60% or ECOG score 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →